2017) for meropenem (86% to 93%), ciprofloxacin (73% to 90%), and piperacillin–tazobactam (80 to 92%), but did not reach statistical significance.
← all excerpts
1988. Impact of a Novel Pharmacist Practice Model on Antimicrobial Usage and Hospital-acquired Clostridium difficile (HACDI) Rates
1
—
—